Athenex Croissance future

Future contrôle des critères 0/6

Le chiffre d'affaires de Athenex devrait diminuer de 23.9% par an, tandis que ses bénéfices annuels devraient croître de 37.6% par an. Le BPA devrait croître de , augmenter de 94.1% par an.

Informations clés

37.6%

Taux de croissance des bénéfices

94.1%

Taux de croissance du BPA

Biotechs croissance des bénéfices	42.4%
Taux de croissance des recettes	-23.9%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	21 Mar 2023

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

DB:2MT0 - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	24	N/A	N/A	N/A	1
12/31/2024	87	-47	N/A	N/A	3
12/31/2023	63	-57	N/A	N/A	2
12/31/2022	103	-98	-77	-75	N/A
9/30/2022	123	-178	-109	-99	N/A
6/30/2022	121	-192	-127	-118	N/A
3/31/2022	109	-198	-144	-136	N/A
12/31/2021	95	-158	-145	-142	N/A
9/30/2021	113	-132	-143	-138	N/A
6/30/2021	117	-135	-137	-130	N/A
3/31/2021	137	-144	-125	-116	N/A
12/31/2020	144	-142	-140	-131	N/A
9/30/2020	157	-118	-132	-120	N/A
6/30/2020	141	-116	-143	-130	N/A
3/31/2020	123	-108	-124	-110	N/A
12/31/2019	101	-123	-111	-97	N/A
9/30/2019	88	-129	-122	-108	N/A
6/30/2019	87	-141	-120	-109	N/A
3/31/2019	77	-145	-137	-130	N/A
12/31/2018	89	-117	-113	-109	N/A
9/30/2018	83	-119	-97	-93	N/A
6/30/2018	78	-96	-74	-71	N/A
3/31/2018	71	-97	-80	-73	N/A
12/31/2017	38	-131	-89	-82	N/A
9/30/2017	28	-143	-83	-76	N/A
6/30/2017	20	-144	-85	-77	N/A
3/31/2017	21	-118	-67	-61	N/A
12/31/2016	21	-88	-52	-48	N/A
9/30/2016	21	-61	N/A	-43	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 2MT0 devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: 2MT0 devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: 2MT0 devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Les revenus de 2MT0 devraient diminuer au cours des 3 prochaines années ( -23.9% par an).

Croissance élevée des revenus: Les revenus de 2MT0 devraient diminuer au cours des 3 prochaines années ( -23.9% par an).

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de 2MT0 devrait être élevé dans 3 ans

Athenex Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Athenex, Inc. Provides Sales Guidance for the Full Year 2022

Athenex, Inc. Reaffirms Sales Guidance for the Year 2021

Recent updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Motion for Asset Sale Filed by Athenex, Inc.

Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C)

Athenex Announces Reverse Stock Split

Athenex Announces MHRA Decision on Oral Paclitaxel

Athenex, Inc. Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

Insufficient new directors

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.33 loss in 3Q 2021)

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Athenex Receives Written Notification from Nasdaq Stating the Company Had Not Regained Compliance with the Rule and Was Ineligible to Obtain A Second 180 Calendar Day Period to Regain Compliance

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $29.995333 million.

Dr. Reddy's, Intas Reportedly in Talks to Buy Athenex

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)

Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

TiHe Capital (Beijing) Co. Ltd. agreed to acquire Chongqing Taihao Pharmaceutical Co., Ltd. and Athenex Pharmaceuticals (Chongqing) Limited from Athenex, Inc. (NasdaqGS:ATNX) for CNY 124 million.

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Athenex, Inc. Provides Sales Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.27 loss in 1Q 2021)

Insufficient new directors

Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular Meetings of ASTCT and CIBMTR

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Athenex Announces Appoints Joe Annoni as Chief Financial Officer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

Athenex, Inc. Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer At SABCS 2021

Independent Director recently bought €54k worth of stock

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)

Independent Director recently bought €136k worth of stock

Chief Financial Officer Randoll Sze has left the company

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)

Athenex, Inc. Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex, Inc. Announces Klisyri® (Tirbanibulin) Receives Positive Chmp Opinion from the European Medicines Agency (Ema) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKTCells in Neuroblastoma at ASGCT Annual Meeting

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020)

Athenex, Inc. Reaffirms Sales Guidance for the Year 2021

Athenex, Inc. (NasdaqGS:ATNX) acquired Kuur Therapeutics Limited.

Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Athenex, Inc

Robbins LLP Reminds Shareholders that Athenex, Inc. is Being Sued for Misleading Shareholders

Insider recently sold €1.6m worth of stock

Independent Director recently sold €385k worth of stock

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

Full year 2020 earnings released: US$1.72 loss per share (vs US$1.67 loss in FY 2019)

New 90-day low: €4.52

Revenue beats expectations

Athenex, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Athenex, Inc. Enters into Second Amendment to the License Agreement

Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy and Safety of Klisyri® (tirbanibulin)

New 90-day high: €11.80

Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

New 90-day low: €9.45

Athenex, Inc. Presents Updated Phase 3 Data on Survival and Tolerability Associated with Oral Paclitaxel and Encequidar in Patients with Metastatic Breast Cancer

Revenue beats expectations

Third quarter 2020 earnings released: US$0.44 loss per share

Athenex, Inc. Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy

Independent Director recently bought €188k worth of stock

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

New 90-day high - €12.20

New 90-day low - €8.85

Athenex, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres